Form 4: Eli Lilly Director Defers Compensation into Stock

Eli Lilly director Gabrielle Sulzberger elected to defer cash compensation into 4.762 shares of common stock, to be settled upon separation from service.

Summary

• Gabrielle Sulzberger, a Director at Eli Lilly & Co (LLY), acquired 4.762 shares of common stock on January 20, 2026.
• The acquisition was a deferral of cash compensation, with the shares being held as stock units under the Lilly Directors' Deferral Plan.
• These stock units will be settled in shares of common stock following Ms. Sulzberger's separation from service.
• The transaction price for the acquired shares was $1,041.29 per share.
• Following this transaction, Ms. Sulzberger beneficially owns 2,961.436 shares of Eli Lilly & Co common stock.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive. While a routine transaction, a director's decision to defer cash compensation into company stock indicates confidence in the company's future and aligns their interests with shareholders, which is generally viewed favorably.

Positives

• The director's election to defer cash compensation into company stock demonstrates a commitment to Eli Lilly's long-term success and aligns her interests with those of shareholders.
• Increasing insider ownership, even through compensation deferral, can be viewed positively by investors as it signals confidence in the company's future performance.

Future Outlook

The acquired stock units will be settled in shares of common stock following the reporting person's separation from service, indicating a future distribution event tied to the director's tenure.

Management Comments

• At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Industry Context

This transaction reflects a common practice in corporate governance where directors elect to receive equity compensation or defer cash compensation into equity, aligning their financial interests with the long-term performance of the company. This is a standard mechanism for director remuneration in the pharmaceutical industry and beyond.

Comparison to Industry Standards

• Many publicly traded companies, including peers in the pharmaceutical sector, offer similar director compensation plans that allow for deferral of fees into company stock or stock units. This practice is considered a standard component of competitive director compensation packages, aiming to foster long-term alignment between directors and shareholders.
• The use of a Rule 10b5-1 plan, as indicated by the check box, is a common and accepted method for insiders to manage stock transactions in compliance with insider trading regulations, providing an affirmative defense against claims of trading on material non-public information.

Stakeholder Impact

• Shareholders: The deferral of compensation into stock by a director enhances alignment between the board and shareholder interests, potentially fostering more shareholder-centric decision-making.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The acquired stock units will be settled in shares of common stock following Gabrielle Sulzberger's separation from service from Eli Lilly & Co.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction related to director compensation deferral. It does not contain any new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction itself, while showing director confidence, is too small and routine to significantly impact the stock's fundamental valuation or market sentiment.

Keywords

Eli Lilly, LLY, Insider Transaction, Form 4, Director Compensation, Stock Deferral, Beneficial Ownership, Corporate Governance